Use of NIR in COVID-19 Screening: Proof of Principles for Future Application.

Publication date: Oct 15, 2024

The COVID-19 pandemic that affected the world between 2019 and 2022 showed the need for new tools to be tested and developed to be applied in global emergencies. Although standard diagnostic tools exist, such as the reverse-transcription polymerase chain reaction (RT-PCR), these tools have shown severe limitations when mass application is required. Consequently, a pressing need remains to develop a rapid and efficient screening test to deliver reliable results. In this context, near-infrared spectroscopy (NIRS) is a fast and noninvasive vibrational technique capable of identifying the chemical composition of biofluids. This study aimed to develop a rapid NIRS testing methodology to identify individuals with COVID-19 through the spectral analysis of swabs collected from the oral cavity. Swab samples from 67 hospitalized individuals were analyzed using NIR equipment. The spectra were preprocessed, outliers were removed, and classification models were constructed using partial least-squares for discriminant analysis (PLS-DA). Two models were developed: one with all the original variables and another with a limited number of variables selected using ordered predictors selection (OPS-DA). The OPS-DA model effectively reduced the number of redundant variables, thereby improving the diagnostic metrics. The model achieved a sensitivity of 92%, a specificity of 100%, an accuracy of 95%, and an AUROC of 94% for positive samples. These preliminary results suggest that NIRS could be a potential tool for future clinical application. A fast methodology for COVID-19 detection would facilitate medical diagnoses and laboratory routines, helping to ensure appropriate treatment.

Open Access PDF

Concepts Keywords
Biofluids Application
Covid Covid
Future Da
Pandemic Develop
Spectroscopy Developed
Diagnostic
Fast
Future
Individuals
Methodology
Nir
Nirs
Rapid
Screening
Variables

Semantics

Type Source Name
disease MESH COVID-19
disease MESH emergencies
disease MESH acute respiratory distress syndrome
disease MESH multiple organ failure
disease MESH death
drug DRUGBANK Gold
disease MESH viral infections
drug DRUGBANK Microcrystalline cellulose
drug DRUGBANK Ethanol
drug DRUGBANK Trestolone
drug DRUGBANK Pidolic Acid
disease IDO algorithm
drug DRUGBANK MCC
drug DRUGBANK Saquinavir
disease MESH complications
disease MESH acute kidney injury
disease MESH delirium
disease MESH encephalopathy
disease MESH cardiomyopathy
disease MESH arrhythmia
disease MESH sudden cardiac death
disease MESH thrombosis
disease MESH hospital infection
drug DRUGBANK Nonoxynol-9
disease MESH COPD
disease MESH Asthma
pathway KEGG Asthma
disease MESH Obesity
disease MESH hypertension
disease MESH diabetes mellitus
disease MESH Sepsis
disease MESH critically ill
drug DRUGBANK Albendazole
drug DRUGBANK Water
disease MESH influenza
disease MESH hepatitis
drug DRUGBANK Coenzyme M
disease MESH Coronavirus Infection
disease IDO site
disease IDO cell
disease MESH Infection
drug DRUGBANK Sulfasalazine

Original Article

(Visited 2 times, 1 visits today)